Study rare gene changes in atypical HUS for tailored care
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) must have atypical HUS (aHUS) with past signs of anemia and low platelets plus kidney problems
- Your recent blood tests should fit the aHUS pattern (low hemoglobin/hematocrit, high LDH, low platelets, and certain blood smear findings)
- You must have negative Coombs test and no detectable haptoglobin, as part of the aHUS diagnosis
- You (or your parent/guardian) must be able to sign informed consent in writing
- You must not have TTP, a specific related blood disorder (very low ADAMTS13 activity)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses RNA sequencing to find genetic causes of rare diseases that standard DNA tests might miss. It may help people who have symptoms of a rare disease but no clear genetic diagnosis yet.
This is a registry that collects information from people diagnosed with atypical hemolytic uremic syndrome (aHUS). It helps researchers better understand the condition across different genetic causes and treatment needs.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
This study looks at how common hemolytic uremic syndrome (HUS) is in children. HUS is a rare condition that affects blood cells and kidneys, and this research will help doctors understand it better.
Hear when a new Atypical Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.